These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

163 related items for PubMed ID: 9973526

  • 1. Adjuvanticity of the cholera toxin A1-based gene fusion protein, CTA1-DD, is critically dependent on the ADP-ribosyltransferase and Ig-binding activity.
    Agren LC, Ekman L, Löwenadler B, Nedrud JG, Lycke NY.
    J Immunol; 1999 Feb 15; 162(4):2432-40. PubMed ID: 9973526
    [Abstract] [Full Text] [Related]

  • 2. Genetically engineered nontoxic vaccine adjuvant that combines B cell targeting with immunomodulation by cholera toxin A1 subunit.
    Agren LC, Ekman L, Löwenadler B, Lycke NY.
    J Immunol; 1997 Apr 15; 158(8):3936-46. PubMed ID: 9103464
    [Abstract] [Full Text] [Related]

  • 3. The B-cell targeted CTA1-DD vaccine adjuvant is highly effective at enhancing antibody as well as CTL responses.
    Lycke N.
    Curr Opin Mol Ther; 2001 Feb 15; 3(1):37-44. PubMed ID: 11249730
    [Abstract] [Full Text] [Related]

  • 4. ADP-ribosylating bacterial enzymes for the targeted control of mucosal tolerance and immunity.
    Lycke N.
    Ann N Y Acad Sci; 2004 Dec 15; 1029():193-208. PubMed ID: 15681758
    [Abstract] [Full Text] [Related]

  • 5. A novel concept in mucosal adjuvanticity: the CTA1-DD adjuvant is a B cell-targeted fusion protein that incorporates the enzymatically active cholera toxin A1 subunit.
    Agren L, Löwenadler B, Lycke N.
    Immunol Cell Biol; 1998 Jun 15; 76(3):280-7. PubMed ID: 9682972
    [Abstract] [Full Text] [Related]

  • 6. Mast cells contribute to the mucosal adjuvant effect of CTA1-DD after IgG-complex formation.
    Fang Y, Larsson L, Mattsson J, Lycke N, Xiang Z.
    J Immunol; 2010 Sep 01; 185(5):2935-41. PubMed ID: 20675596
    [Abstract] [Full Text] [Related]

  • 7. The nontoxic CTA1-DD adjuvant enhances protective immunity against Helicobacter pylori infection following mucosal immunization.
    Akhiani AA, Stensson A, Schön K, Lycke N.
    Scand J Immunol; 2006 Feb 01; 63(2):97-105. PubMed ID: 16476008
    [Abstract] [Full Text] [Related]

  • 8. The ADP-ribosylating CTA1-DD adjuvant enhances T cell-dependent and independent responses by direct action on B cells involving anti-apoptotic Bcl-2- and germinal center-promoting effects.
    Agren L, Sverremark E, Ekman L, Schön K, Löwenadler B, Fernandez C, Lycke N.
    J Immunol; 2000 Jun 15; 164(12):6276-86. PubMed ID: 10843681
    [Abstract] [Full Text] [Related]

  • 9. Complement activation and complement receptors on follicular dendritic cells are critical for the function of a targeted adjuvant.
    Mattsson J, Yrlid U, Stensson A, Schön K, Karlsson MC, Ravetch JV, Lycke NY.
    J Immunol; 2011 Oct 01; 187(7):3641-52. PubMed ID: 21880985
    [Abstract] [Full Text] [Related]

  • 10. The B cell targeted adjuvant, CTA1-DD, exhibits potent mucosal immunoenhancing activity despite pre-existing anti-toxin immunity.
    Lycke N, Schön K.
    Vaccine; 2001 Mar 21; 19(17-19):2542-8. PubMed ID: 11257390
    [Abstract] [Full Text] [Related]

  • 11. From toxin to adjuvant: basic mechanisms for the control of mucosal IgA immunity and tolerance.
    Lycke N.
    Immunol Lett; 2005 Mar 15; 97(2):193-8. PubMed ID: 15752558
    [Abstract] [Full Text] [Related]

  • 12. CTA1-DD is an effective adjuvant for targeting anti-chlamydial immunity to the murine genital mucosa.
    Cunningham KA, Carey AJ, Lycke N, Timms P, Beagley KW.
    J Reprod Immunol; 2009 Jul 15; 81(1):34-8. PubMed ID: 19501917
    [Abstract] [Full Text] [Related]

  • 13. [Cholera immunology and the molecular biology of cholera toxin. Recent progress and future prospects].
    Carrada Bravo T.
    Rev Alerg; 1993 Jul 15; 40(4):91-4. PubMed ID: 8143024
    [Abstract] [Full Text] [Related]

  • 14. The universal influenza vaccine M2e-HBc administered intranasally in combination with the adjuvant CTA1-DD provides complete protection.
    De Filette M, Ramne A, Birkett A, Lycke N, Löwenadler B, Min Jou W, Saelens X, Fiers W.
    Vaccine; 2006 Jan 30; 24(5):544-51. PubMed ID: 16169634
    [Abstract] [Full Text] [Related]

  • 15. From toxin to adjuvant: the rational design of a vaccine adjuvant vector, CTA1-DD/ISCOM.
    Lycke N.
    Cell Microbiol; 2004 Jan 30; 6(1):23-32. PubMed ID: 14678328
    [Abstract] [Full Text] [Related]

  • 16. A novel non-toxic combined CTA1-DD and ISCOMS adjuvant vector for effective mucosal immunization against influenza virus.
    Eliasson DG, Helgeby A, Schön K, Nygren C, El-Bakkouri K, Fiers W, Saelens X, Lövgren KB, Nyström I, Lycke NY.
    Vaccine; 2011 May 23; 29(23):3951-61. PubMed ID: 21481325
    [Abstract] [Full Text] [Related]

  • 17. The cholera toxin-derived CTA1-DD vaccine adjuvant administered intranasally does not cause inflammation or accumulate in the nervous tissues.
    Eriksson AM, Schön KM, Lycke NY.
    J Immunol; 2004 Sep 01; 173(5):3310-9. PubMed ID: 15322194
    [Abstract] [Full Text] [Related]

  • 18. Cholera toxin promotes B cell isotype switching by two different mechanisms. cAMP induction augments germ-line Ig H-chain RNA transcripts whereas membrane ganglioside GM1-receptor binding enhances later events in differentiation.
    Lycke NY.
    J Immunol; 1993 Jun 01; 150(11):4810-21. PubMed ID: 8388421
    [Abstract] [Full Text] [Related]

  • 19. Hydrophobicity engineering of cholera toxin A1 subunit in the strong adjuvant fusion protein CTA1-DD.
    Agren L, Norin M, Lycke N, Löwenadler B.
    Protein Eng; 1999 Feb 01; 12(2):173-8. PubMed ID: 10195289
    [Abstract] [Full Text] [Related]

  • 20. CTA1-M2e-DD: a novel mucosal adjuvant targeted influenza vaccine.
    Eliasson DG, El Bakkouri K, Schön K, Ramne A, Festjens E, Löwenadler B, Fiers W, Saelens X, Lycke N.
    Vaccine; 2008 Feb 26; 26(9):1243-52. PubMed ID: 18243429
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.